<DOC>
	<DOCNO>NCT01294150</DOCNO>
	<brief_summary>The purpose study evaluate safety effectiveness UroLift ( R ) System used subject symptomatic benign hyperplasia ( BPH ) . Primary effectiveness achieve look improvement International Prostate Symptom Score ( IPSS ) safety review base pertinent adverse event .</brief_summary>
	<brief_title>The Safety Effectiveness UroLift : LIFT Pivotal Study</brief_title>
	<detailed_description>The randomized portion study prospective , multicenter , multinational , 2:1 randomize , single-blinded control clinical trial compare IPSS treatment group IPSS control group 3 month follow-up . Subjects active treatment group undergo UroLift system treatment . Subjects control group undergo cystoscopy procedure . All subject follow 12 month , 5 year receive investigational device .</detailed_description>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Lower Urinary Tract Symptoms</mesh_term>
	<criteria>Males age 50 year old diagnose symptomatic benign prostatic hyperplasia ( BPH ) Size , volume , length prostate</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>